The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2021 | Novel targets, therapies and combinations for myeloma
Enrique Ocio, MD, PhD, of Marqués de Valdecilla University Hospital, Santander, Spain, speaks on novel targets, therapies, and combinations for multiple myeloma, and comments on future directions for its treatment. In particular, Dr Ocio talks on the novel agents which have gained FDA approval such as selinexor, melflufen, and belantamab mafodotin, as well as discussing the role of combinatorial approaches. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Enrique M. Ocio, MD, PhD, has received honoraria or consultancy fees from Janssen, BMS, Sanofi, GSK, Oncopeptides, Amgen, Takeda, Secura-Bio, MSD and Mundipharma-EDO.
